Clinical TrialMay 22, 2026, 07:02 AM
AC Immune's ACI-19626 PET Tracer Shows Higher Uptake in ALS Patients
AI Summary
AC Immune announced new preliminary Phase 1 data for its first-in-class TDP-43 PET tracer ACI-19626, demonstrating significantly higher uptake in key brain regions of patients with amyotrophic lateral sclerosis (ALS) compared to healthy controls. These results, presented at the 2026 TDP43 Summit, build upon previous findings showing detection of TDP-43 in patients with genetic frontotemporal dementia (FTD). The tracer continues to exhibit good safety, tolerability, and a pharmacokinetic profile suitable for human brain imaging, underscoring its potential for early diagnosis and precision medicine in neurodegenerative diseases.
Key Highlights
- AC Immune's ACI-19626 PET tracer showed significantly higher uptake in key brain regions of ALS patients.
- Tracer uptake was notably higher in the brain stem and precentral gyrus in ALS patients.
- Previously reported data also showed ACI-19626 detected TDP-43 in patients with genetic frontotemporal dementia (FTD).
- ACI-19626 demonstrated good safety, tolerability, and a suitable pharmacokinetic profile for human brain imaging.
- The ongoing Phase 1 trial (NCT06891716) is expanding to include up to 30 patients with FTD, ALS, or LATE.
- CEO Dr. Andrea Pfeifer emphasized the tracer's potential for early diagnosis and precision medicine.
Price Impact
More from ACIU